|View printer-friendly version|
Spring Bank Pharmaceuticals Provides Corporate Update and Reports 2016 Financial and Operational Results
“Spring Bank reported a number of significant events in 2016, including financings that generated gross proceeds to us of approximately
“More specifically, the fourth quarter of 2016 was a productive period for
2016 Financial Results
Any statements in this press release about Spring Bank’s future expectations, plans and prospects, including statements about (i) the company having sufficient funds to (a) complete its ongoing Phase 2a trial of SB 9200 and generate all of the SB 9200 monotherapy dosing data and (b) advance SB 11285 further towards a potential IND submission in 2018, (ii) the company having sufficient funds to enable it to fund its operating expenses and capital expenditure requirements at least into the third quarter of 2018, (iii) the company’s anticipated timeline for disclosing top-line results from the first SB 9200 monotherapy dosing cohort in the Phase 2a trial of SB 9200, (iv) the potential consummation of additional development collaborations for SB 9200 in HBV and (v) the anticipated publication of preclinical data for SB 11285, as well as any other statements containing the words "believes," "anticipates," "estimates," "expects," "intends," "plans," "predicts," "projects," "targets," "may," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether Spring Bank’s cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; whether results obtained in preclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether Spring Bank’s product candidates will advance through the clinical trial process on a timely basis or at all; whether the results of such trials will warrant submission for approval from the
In addition, the forward-looking statements included in this press release represent Spring Bank’s views as of the date hereof.